Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 1, 2006 Ron Feemster	Good Counsel Law the Pfizer way: Crack down on counterfeiters, build a private police force, and make nice with the Office of the Inspector General. Then hire a foreign-policy expert.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
BusinessWeek December 9, 2010 Tom Randall	At Pfizer, a Messy Passing of the Mantle CEO Jeffrey Kindler resigned abruptly before a special board meeting. His successor, Ian Read, will get no honeymoon
BusinessWeek October 31, 2008 Arlene Weintraub	Pfizer CEO Kindler Has His Work Cut Out for Him Investors want a fresh perspective for post-Lipitor Pfizer, but they're not yet convinced outsider CEO Jeffrey Kindler is the one to bring it.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool December 7, 2010 Brian Orelli	How Pfizer's New Chief Can Right the Ship Bigger is not always better.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool February 2, 2010 Brian Orelli	Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
BusinessWeek November 24, 2010 Tom Randall	Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool October 22, 2007 Brian Lawler	Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer Is "At a Fork in the Road" CEO Henry McKinnell discusses the drugmaker's outlook, from new products and advertising to the challenges facing health care.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool January 24, 2008 Brian Lawler	Pfiltering Through Pfizer's Year Pfizer releases its 2007 numbers, displaying year-over-year earnings growth powered by foreign currency gains.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
Pharmaceutical Executive January 1, 2007 Walter Armstrong	Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.